α1受体阻滞剂治疗男性神经原性膀胱逼尿肌尿道外括约肌功能失调的临床研究  

Clinical effect of alpha-1 adrenoceptor blocker on neurologic detrusor sphincter dyssynergia

作　　者：陈晖[1] 蒋重和 汤平[3] 欧汝彪[3] 曾健文[2] 邓向荣[3] 周理林[2] 黄马平[1] 李青青[1] 刘秋玲[1] 黄杰滨 谢克基[3] 

机构地区：[1]广东省工伤康复中心泌尿外科,广东广州510440 [2]暨南大学附属广东省清远市人民医院泌尿外科,广东清远511500 [3]广州医科大学附属广州市第一人民医院泌尿外科,广东广州510180

出　　处：《现代泌尿外科杂志》2015年第6期376-379,共4页Journal of Modern Urology

基　　金：广东省科技计划项目(No.2012B031800007);广东省医学科研基金项目(No.A2013477)

摘　　要：目的探讨α1受体阻滞剂治疗男性神经原性逼尿肌尿道外括约肌功能失调（NDSD）疗效和安全性。方法采用前瞻性、多中心、单盲、随机对照的试验方法,2012年6月~2014年10月男性神经原性逼尿肌尿道外括约肌功能失调患者,分为实验组和对照组,实验组予患者口服盐酸坦索罗辛缓释胶囊0.2mg/d,对照组予安慰剂治疗,观察服药后4周和12周的泌尿生殖系困扰调查的6项短表（UDI-6）、平均膀胱剩余尿量（PVR）、间歇导尿（IC）患者例数、平均每日IC次数,服药后12周平均最大尿流率（Qmax）、平均最大尿流率时膀胱逼尿肌压力（Pdet.Qmax）、平均最大尿道闭合压（MUCP）,并记录相关不良事件。采用SPSS13.0统计学软件。计量资料采用t检验,计数资料采用卡方检验。结果入选患者94例,88例患者完成试验（实验组46例,对照组42例）。实验组和对照组的基线数据比较差异无统计学意义（P〉0.05）。服药后4和12周实验组和对照组间UDI-6、PVR、IC患者例数、平均每日IC次、Qmax、Pdet.Qmax和MUCP比较差异均有统计学意义（P〈0.05）。服药后4和12周实验组UDI-6、PVR、IC患者例数、平均每日IC次、Qmax、Pdet.Qmax和MUCP和基线值比较差异也均有统计学意义（P〈0.05）。结论α1受体阻滞剂能改善男性NDSD排尿,提高患者生命质量。Objective To evaluate the efficacy and safety of alpha-1 adrenoceptor blocker for neurologic detrusor sphinc- ter dyssynergia （NDSD）. Methods A prospective, multicenter, single-blind and randomized controlled trial was conducted during Jun. 2012 and Oct. 2014. Patients with NDSD were recruited and randomly divided into experimental group and control group. The experimental group received tamsulosin 0.2 mg/d, while the control group took placebo. Indexes including UDI-6, PVR, IC cases, frequency of IC, Qmax, Pdet. Qmax and MUCP were tested. Related adverse events were recorded. Data col- lected were analyzed with SPSS 13.0 software, t-test and chi-squared method. Results A total of 94 patients were recruited and 86 of them completed the trail （46 cases in experimental group, 42 in control group）. There were no significant differences in baseline evaluation items between the two groups （P〉0.05）. In week 4 and 12 during follow-up, there were significant differences in UDI-6, PVR, IC cases, frequency of IC, Qmax, Pdet. Qmax and MUCP between the two groups （P〈0.05）. In week 12, all outcomes improved significantly compared to baseline in the experimental group （P〈0. 05）. Conclusi.ons Al- pha-1 adrenoceptor blocker is effective and safe for patients with NDSD. It can improve patients＇ urination and quality of life.

关 键 词：Α1受体阻滞剂 神经原性逼尿肌尿道外括约肌功能失调 疗效 安全性 

分 类 号：R69[医药卫生—泌尿科学]